FEATURE ARTICLES
Quality requirements for parenteral drugs complicate facility design like few other regulated products. If you're developing injectables, be aware of these key issues.
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- The Rise Of The Autonomous Pharma Plant
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
- At Base Camp: Lilly's Manufacturing Capacity Journey
- The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
- January 2026 — CDMO Opportunities And Threats Report
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-2174865889-scientists-laboratory-equipment-analysis]( "Process Analytical Technology In The ADC Bioconjugation Process")
Process Analytical Technology In The ADC Bioconjugation ProcessIntegrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
-
Sustainability In Small Molecule API Manufacturing11/7/2025
Redesigning chemical processes with green chemistry principles can cut emissions, reduce waste, and improve efficiency. See how smarter synthesis and digital tools enable sustainable API manufacturing.
-
5 Steps To Design A Microbiological Performance Qualification For Facilities4/21/2025Explore five steps to design an EMPQ for sterile manufacturing: classification, protocol drafting, cleaning evaluation, disinfectant efficacy testing, and continuous improvement.
-
Enabling Digital Twins With Computational Fluid Dynamics Modeling1/16/2025
Embrace the transformative power of predictive modeling and digital twin technology to optimize bioprocess efficiency, ensure product quality, and drive innovation in biopharmaceutical manufacturing.
-
Accelerating Antibody-Drug Conjugate (ADC) Development10/29/2025
Explore how automated immunoassays help overcome ADC bioanalysis challenges, reducing hands-on time, improving throughput, and enabling multi-analyte workflows for more efficient assessments.
-
Driving Digital Excellence In Life Sciences7/1/2025
The life sciences industry is rapidly evolving through digital transformation and agility. Discover why embracing modern technologies is essential to thrive in today’s competitive landscape.
PHARMA ONLINE APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 02.26.26 -- At Base Camp: Lilly's Manufacturing Capacity Journey
- 02.26.26 -- STREAM Edition: Considerations For Single Use Disposables
- 02.25.26 -- Ready to design a scalable, cost optimized viral vector workflow?
- 02.25.26 -- Advanced Mixing Strategies & Process Optimization
- 02.24.26 -- Innovations Shaping The Future Of Pharma Manufacturing
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas2/26/2026
Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas.
-
Bora Pharmaceuticals And GSK Sign $250M Five Year Global Manufacturing Contract2/24/2026
This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest OSD site in Maple Grove, Minnesota.
-
AbbVie Announces $380 Million Investment With Two New Active Pharmaceutical Ingredient Manufacturing Facilities In Illinois2/24/2026
AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.
-
Johnson & Johnson Announces $1 Billion Investment With New Cell Therapy Manufacturing Facility In Pennsylvania2/22/2026
ohnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.
